Abstract
Butyric acid (NaBut) and its derivatives are well-known agents eliciting tumor cell differentiation and apoptosis. In experimental models, NaBut is also used to enhance the efficacy of viral vectors. With the use of B78 murine melanoma cells transduced with the retroviral vector containing human tumor necrosis factor a (hTNF-α) gene, we investigated the ability of NaBut to increase the cytokine expression. We observed an increase in hTNF-α expression in vitro after incubation with NaBut. We also describe that the NaBut pro-drug tributyrin is able to increase hTNF-α expression in transduced B78 cells in a tumor vaccination model in mice. This observation strongly suggests a novel potential role for NaBut and its derivatives in tumor therapy. It could be used not only as a therapeutic directly acting on tumor cells but, in parallel, as a genetic vaccine "enhancer".
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4001-4004 |
| Number of pages | 4 |
| Journal | Anticancer Research |
| Volume | 21 |
| Issue number | 6 A |
| State | Published - 2001 |
| Externally published | Yes |
Fingerprint
Keywords
- Cancer
- Retroviral vector
- Sodium butyrate
- TNF-α
- Tributyrin
- Vaccine
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Butyric acid enhances in vivo expression of hTNF-α in transduced melanoma cell line. / Giermasz, Adam; Grzela, Tomasz; Nowis, Dominika; Makowski, Marcin; Czajka, Anna; Stoklosa, Tomasz; Lasek, Witold; Dabrowska, Anna; Wiznerowicz, Maciej; Mackiewicz, Andrzej; Jakóbisiak, Marek.
In: Anticancer Research, Vol. 21, No. 6 A, 2001, p. 4001-4004.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Butyric acid enhances in vivo expression of hTNF-α in transduced melanoma cell line
AU - Giermasz, Adam
AU - Grzela, Tomasz
AU - Nowis, Dominika
AU - Makowski, Marcin
AU - Czajka, Anna
AU - Stoklosa, Tomasz
AU - Lasek, Witold
AU - Dabrowska, Anna
AU - Wiznerowicz, Maciej
AU - Mackiewicz, Andrzej
AU - Jakóbisiak, Marek
PY - 2001
Y1 - 2001
N2 - Butyric acid (NaBut) and its derivatives are well-known agents eliciting tumor cell differentiation and apoptosis. In experimental models, NaBut is also used to enhance the efficacy of viral vectors. With the use of B78 murine melanoma cells transduced with the retroviral vector containing human tumor necrosis factor a (hTNF-α) gene, we investigated the ability of NaBut to increase the cytokine expression. We observed an increase in hTNF-α expression in vitro after incubation with NaBut. We also describe that the NaBut pro-drug tributyrin is able to increase hTNF-α expression in transduced B78 cells in a tumor vaccination model in mice. This observation strongly suggests a novel potential role for NaBut and its derivatives in tumor therapy. It could be used not only as a therapeutic directly acting on tumor cells but, in parallel, as a genetic vaccine "enhancer".
AB - Butyric acid (NaBut) and its derivatives are well-known agents eliciting tumor cell differentiation and apoptosis. In experimental models, NaBut is also used to enhance the efficacy of viral vectors. With the use of B78 murine melanoma cells transduced with the retroviral vector containing human tumor necrosis factor a (hTNF-α) gene, we investigated the ability of NaBut to increase the cytokine expression. We observed an increase in hTNF-α expression in vitro after incubation with NaBut. We also describe that the NaBut pro-drug tributyrin is able to increase hTNF-α expression in transduced B78 cells in a tumor vaccination model in mice. This observation strongly suggests a novel potential role for NaBut and its derivatives in tumor therapy. It could be used not only as a therapeutic directly acting on tumor cells but, in parallel, as a genetic vaccine "enhancer".
KW - Cancer
KW - Retroviral vector
KW - Sodium butyrate
KW - TNF-α
KW - Tributyrin
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=0035570832&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035570832&partnerID=8YFLogxK
M3 - Article
VL - 21
SP - 4001
EP - 4004
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 6 A
ER -